Analyst Ratings for Eli Lilly (LLY)
LLY Rating Summary
LLY Price Target Summary
- Highest: $364.00 (Morgan Stanley)
- Lowest: $236.00 (Goldman Sachs)
- Average: $303.05
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$303.05 (-5.5%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 63%
Rating Score: 6.3 / 10

Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
5/23/2022 | SVB Leerink | Andrew Berens | New Coverage | Outperform (N/A) |
341.00 (N/A) |
286.27 (320.81) |
12.07% | Details |
3/10/2022 | Daiwa Securities | N/A | New Coverage | Buy (2) (N/A) |
286.00 (N/A) |
259.93 (320.81) |
23.42% | Details |
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
LLY Ratings News
- Cantor Fitzgerald Reiterates Overweight Rating, $335 Price Target on Eli Lilly (LLY)
- Eli Lilly's (LLY) Latest Mounjaro Efficacy Data "Unmatched", Analyst Sees More Upside, Reiterates Stock as Top Pick - Mizuho Securities Bullish with $365 Price Target
- UPDATE: SVB Leerink Assumes Eli Lilly (LLY) at Outperform, 'Own the Game-Changer'
- See More